A newly approved drug called oveporexton represents a significant advance in the treatment of narcolepsy, a neurological disorder characterized by sudden bouts of deep sleep and muscle weakness known as cataplexy. The medication was recently authorised by the US Food and Drug Administration and is currently under evaluation by the UK’s National Institute for Health and Care Excellence (NICE) to determine whether its annual cost—estimated at around £120,000 per patient—is justified for use within the National Health Service. A decision from NICE is expected by April 2027.
Oveporexton is the first drug to address the underlying cause of the most common type of narcolepsy, type-1, which accounts for approximately 75% of cases. The condition is believed to arise when the immune system mistakenly attacks brain cells responsible for producing orexin, a peptide that regulates wakefulness. By stimulating orexin receptors outside these brain cells, oveporexton boosts orexin levels, helping to control sleep-wake cycles.
Narcolepsy affects an estimated 30,000 people in the UK, typically striking children and young adults. Symptoms include sudden sleep attacks lasting up to 20 minutes, often accompanied by cataplexy—a brief loss of muscle control triggered by strong emotions such as laughter or surprise. Episodes may be followed by temporary sleep paralysis, during which patients cannot move or speak.
Existing treatments include modafinil, a stimulant that encourages the brain to release stress hormones to promote alertness, and sodium oxybate, which patients take at night to enhance deep sleep. However, both carry risks: modafinil has been associated with irregular heartbeats and blood pressure spikes, while sodium oxybate can cause side effects ranging from dizziness and nausea to memory loss and sleepwalking.
Clinical trials involving over 270 narcolepsy patients showed that oveporexton, administered twice daily for three months, significantly improved daytime alertness and reduced cataplexy episodes by about 80%. Side effects were generally mild and included insomnia and increased urination. Experts like Guy Leschziner, professor of neurology and sleep medicine at Guy’s and St Thomas’ Hospital in London, have described the drug as a breakthrough, long anticipated in the field of narcolepsy treatment.
Beyond narcolepsy, researchers are exploring the potential of orexin-targeting drugs for other conditions. These include sleep apnoea—a disorder characterized by interrupted breathing during sleep—attention deficit hyperactivity disorder (ADHD), depression, and addictive behaviours. Early reports suggest narcolepsy patients on oveporexton have experienced improvements in attention, prompting interest in these broader applications.
Long-term studies have indicated that narcolepsy may increase the risk of premature death by up to 30%, largely due to associated health complications like heart disease, diabetes, and mental illness stemming from chronic sleep disruption. The development of drugs like oveporexton aims to reduce these risks by better managing the core dysfunction of the disorder.
Oveporexton belongs to a new class of treatments known as orexin receptor-2 agonists and is the culmination of nearly three decades of research seeking to compensate for orexin deficiency in narcolepsy patients. As regulatory decisions and further studies progress, patients and clinicians are hopeful this medication will offer substantial benefits for those living with this challenging condition.